scispace - formally typeset
D

David Cameron

Researcher at University of Oslo

Publications -  1765
Citations -  141776

David Cameron is an academic researcher from University of Oslo. The author has contributed to research in topics: Large Hadron Collider & Breast cancer. The author has an hindex of 154, co-authored 1586 publications receiving 126067 citations. Previous affiliations of David Cameron include Universidade Nova de Lisboa & Cameron International.

Papers
More filters
Journal ArticleDOI

Measurement of the ZZ Production Cross Section and Limits on Anomalous Neutral Triple Gauge Couplings in Proton-Proton Collisions at root s=7 TeV with the ATLAS Detector

Georges Aad, +3020 more
TL;DR: A measurement of the ZZ production cross section in proton-proton collisions at root s = 7 TeV using data corresponding to an integrated luminosity of 1.02 fb(-1) recorded by the ATLAS experiment a...
Journal ArticleDOI

Optical and electronic properties of carbon nitride

TL;DR: A brief review of the current state of knowledge about carbon nitride properties can be found in this article, where the authors try to extract some generally applicable results from the span of those which have been reported.
Journal ArticleDOI

Search for charged Higgs bosons through the violation of lepton universality in tt events using pp collision data at √S=7 TeV with the ATLAS experiment

Georges Aad, +2935 more
TL;DR: In this article, an analysis based on 4.6 fb(-1) of proton-proton collision data at root s = 7 TeV collected by the ATLAS experiment at the Large Hadron Collider is presented.
Journal ArticleDOI

Search for W′→tb→qqbb decays in pp collisions at √s = 8 TeV with the ATLAS detector

Georges Aad, +2872 more
TL;DR: In this article, a search for a massive gauge boson decaying to a top quark and a bottom quark is performed with the ATLAS detector in [Formula: see text] collisions at the LHC.
Journal ArticleDOI

Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data

TL;DR: Geyer et al. as mentioned in this paper reported updated efficacy data and results of correlative studies to determine if gene expression levels in the 5-FU and HER pathways are associated with clinical benefit in L+C.